- Report
- February 2024
- 126 Pages
Global
From €2875EUR$2,990USD£2,466GBP
- Report
- May 2024
- 354 Pages
Global
From €5385EUR$5,600USD£4,619GBP
- Report
- February 2021
- 342 Pages
Global
From €3606EUR$3,750USD£3,093GBP
- Drug Pipelines
- January 2018
- 8 Pages
Global
From €9615EUR$10,000USD£8,249GBP
- Drug Pipelines
- January 2018
- 8 Pages
Global
From €9615EUR$10,000USD£8,249GBP
- Drug Pipelines
- January 2018
- 14 Pages
Global
From €9615EUR$10,000USD£8,249GBP
Injectafer is a brand of hematological drugs used to treat iron deficiency anemia. It is a form of iron sucrose, an iron-based compound that is injected intravenously. The drug is used to replenish iron stores in the body, which can help improve anemia symptoms such as fatigue, weakness, and shortness of breath. Injectafer is approved for use in adults and children over the age of 12.
Injectafer is part of a larger market of hematological drugs, which includes treatments for blood disorders such as anemia, hemophilia, and sickle cell disease. These drugs are used to treat a variety of conditions, from mild to severe. They can be administered orally, intravenously, or subcutaneously.
Some companies in the Injectafer market include Vifor Pharma, Fresenius Kabi, and American Regent. These companies produce and distribute the drug, as well as other hematological drugs. Show Less Read more